ArticleNature genetics2023
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Open access · hybridAbstract read
In one paragraph
Article in Nature genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.
0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed
39.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 169 citations in OpenAlex.
- Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.Cancer communications (London, England) · 2026Trial
- Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.Journal for immunotherapy of cancer · 2024Trial
- Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).Cell reports. Medicine · 2024Trial
- Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1.Science advances · 2026Article
- Clinical attribute-based risk matrix for prognostication in immunotherapy-treated non-small cell lung cancer.Nature communications · 2026Article
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Generalizable AI predicts immunotherapy outcomes across cancers and treatments.Nature medicine · 2026Article
- Quantum convolutional HLA immunogenic peptide prediction (Q-CHIPP): Next-generation neoantigen prediction with quantum neural network.Science advances · 2026Article
- Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma.Cell reports. Medicine · 2026Article
- An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy.EBioMedicine · 2026Article
- SERPINA3 as a Secreted-Protein Biomarker Associated with Poor Prognosis and T-Cell Dysfunction in Non-small Cell Lung Cancer.Tuberculosis and respiratory diseases · 2026Article
- Advances in delivery technologies-powered cancer vaccines.Bioactive materials · 2026Review
- SP-printer: reconstruction of tumor stage-specific microenvironments via phenotype-integrated spatial transcriptomics.Journal of translational medicine · 2026Article
- Article
- Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer.PLoS biology · 2026Article
- Aberrant expression of GBP5 in tumor-infiltrating immune cells as an onco-immunological biomarker in pan-cancer.Discover oncology · 2026Article
- Article
- Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment.Cell reports. Medicine · 2026Article
- Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC.The Journal of clinical investigation · 2026Article
- Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 17 institutions in 2 countries.
Arvind Ravi *Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Matthew D Hellmann *AstraZeneca, Oncology R&D, New York, NY, USA.
Monica B Arniella *Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7286-0590
Mark HoltonBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Samuel S FreemanBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8285-0057
Vivek NaranbhaiMassachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
Chip StewartBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Ignaty LeshchinerBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8942-9265
Jaegil KimGlaxoSmithKline, Waltham, MA, USA.
Yo AkiyamaBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6662-1289
Aaron T GriffinHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Natalie I VokesDepartment of Thoracic and Head and Neck Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3766-5335
Mustafa SakhiCenter for Thoracic Cancers, Massachusetts General Hospital, Boston, MA, USA.
Vashine KamesanCenter for Thoracic Cancers, Massachusetts General Hospital, Boston, MA, USA.
Hira RizviDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Biagio RicciutiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrick M FordeBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6925-6344
Valsamo AnagnostouBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-9480-3047
Jonathan W RiessUC Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Don L GibbonsDepartment of Thoracic and Head and Neck Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2362-3094
Nathan A PennellDepartment of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Vamsidhar VelchetiDepartment of Hematology and Oncology, NYU Langone Health, New York, NY, USA.
Subba R DigumarthyDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Mari Mino-KenudsonDepartment of Medicine, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9092-2265
Andrea CalifanoHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
John V HeymachDepartment of Thoracic and Head and Neck Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9068-8942
Roy S HerbstYale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-2535-5847
Julie R BrahmerBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kurt A SchalperYale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-5692-4833
Victor E VelculescuBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-1195-438X
Brian S HenickHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0003-2681-0805
Naiyer RizviSynthekine, Inc., Menlo Park, CA, USA.
Pasi A JänneLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7821-4928
Mark M AwadLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew ChowDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-1151-2450
Benjamin D GreenbaumComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-6153-8793
Marta LukszaDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alice T ShawCenter for Thoracic Cancers, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6337-1093
Jedd WolchokWeill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-6718-2222
Nir HacohenBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. nhacohen@broadinstitute.org.ORCID http://orcid.org/0000-0002-2349-2656
Gad GetzBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. gadgetz@broadinstitute.org.ORCID http://orcid.org/0000-0002-0936-0753
Justin F GainorMassachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA, USA. jgainor@mgh.harvard.edu.
Broad Institute · USHarvard University · USBloomberg (United States) · USMassachusetts General Hospital · USColumbia University Irving Medical Center · USMemorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · USYale Cancer Center · USAstraZeneca (United States) · USCentre for the AIDS Programme of Research in South Africa · ZACleveland Clinic · USCornell University · USGlaxoSmithKline (United States) · USIcahn School of Medicine at Mount Sinai · USNYU Langone Health · USSynthego (United States) · USUC Davis Comprehensive Cancer Center
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MStaff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007367 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI REINER, STEVEN L · 1985 to 2021
$25.1MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MTraining Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8MPredicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5MUC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4MSystematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer MedicineU01CA217858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2017 to 2021
$6.1MElucidating and Targeting tumor dependencies and drug resistance determinants at the single cell levelU01CA272610 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2022 to 2026
$4.8MPatho-Genetic Analysis of Invasive Mucinous Adenocarcinoma of the LungR01CA240317 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI MAEDA, YUTAKA, SNYDER, ERIC LEE · 2020 to 2024
$3.1MNCATS NIH HHS UL1 TR001863NCI NIH HHS F30 CA257765NCI NIH HHS K08 CA248723NCI NIH HHS K12 CA138464NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA208756NCI NIH HHS R01 CA240317NCI NIH HHS R35 CA197745NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA217858NCI NIH HHS U01 CA272610NHGRI NIH HHS T32 HG002295NIGMS NIH HHS T32 GM007367NIH HHS S10 OD012351NIH HHS S10 OD021764NIH HHS S10 OD032433
Abstract
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with NSCLC treated with anti-PD-(L)1 therapy, along with matched clinical response annotation. We identify a number of associations between molecular features and outcome, including (1) favorable (for example, ATM altered) and unfavorable (for example, TERT amplified) genomic subgroups, (2) a prominent association between expression of inducible components of the immunoproteasome and response and (3) a dedifferentiated tumor-intrinsic subtype with enhanced response to checkpoint blockade. Taken together, results from this cohort demonstrate the complexity of biological determinants underlying immunotherapy outcomes and reinforce the discovery potential of integrative analysis within large, well-curated, cancer-specific cohorts.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsGenomicsHumansProgrammed Cell Death 1 ReceptorTranscriptomeProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.